Plaque Psoriasis
📧 Sign up to get email alerts when something new happens for Plaque Psoriasis.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2025-07-18FDA Approved: FLUOCINOLONE ACETONIDE OIL — Supplemental Application (Rising Pharma Holdings, Inc.)
The FDA approved a supplemental application for Fluocinonide Acetonide Oil, a topical corticosteroid product from Rising Pharma Holdings, In…
-
CLINICAL_TRIALS trial_result · 2025-07-18Clinical Trial Update: Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis [Phase 3]
Phase 3 study comparing guselkumab versus placebo in patients with low body surface area moderate plaque psoriasis has completed.
-
CLINICAL_TRIALS research · 2025-07-17Clinical Trial Update: Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications
A clinical trial assessing pregnancy outcomes in risankizumab-exposed pregnancies versus non-exposed pregnancies in women with FDA-approved …
-
CLINICAL_TRIALS trial_result · 2025-07-16Clinical Trial Update: Phase II Study Evaluating the Clinical Efficacy and Safety of GN-037 in Plaque Psoriasis [Phase 2]
Phase II study evaluating the clinical efficacy and safety of GN-037 in plaque psoriasis has completed.
-
CLINICAL_TRIALS research · 2025-07-14Clinical Trial Update: A Trial Comparing SHR-1139 Injection With Placebo in Patients With Moderate-to-severe Plaque Psoriasis [Phase 2]
Phase 2 clinical trial comparing SHR-1139 injection with placebo in adults with moderate-to-severe plaque psoriasis; the study is currently …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-06-24Clinical Trial Update: Study of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Netakimab in Children With Moderate to Severe Plaque Psoriasis [Phase 3]
Ongoing Phase 3 trial evaluating netakimab in children with moderate to severe plaque psoriasis; status is active but not recruiting.
-
CLINICAL_TRIALS research · 2025-06-24Clinical Trial Update: A Study to Assess Patient-Reported Wellbeing Using Tildrakizumab in a Live Setting
A clinical trial assessing patient-reported wellbeing in plaque psoriasis using tildrakizumab; the study is currently active but not recruit…
-
CLINICAL_TRIALS research · 2025-06-17Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ASC50 Tables in Healthy Participants and Participants With Plaque Psoriasis [Phase 1]
A Phase 1 study is evaluating ASC50 tablets in healthy participants and individuals with plaque psoriasis to assess safety, tolerability, ph…
-
CLINICAL_TRIALS trial_result · 2025-06-15Clinical Trial Update: Ayurvedic Treatment Package in Plaque Psoriasis [Phase 3]
A Phase 3 clinical trial evaluating an Ayurvedic treatment package for plaque psoriasis has completed. The excerpt does not provide trial re…
-
CLINICAL_TRIALS trial_result · 2025-06-06Clinical Trial Update: Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis [Phase 3]
Phase 3 trial evaluating tildrakizumab for nail psoriasis in chronic plaque psoriasis; results have been posted.
-
CLINICAL_TRIALS trial_result · 2025-06-03Clinical Trial Update: Interleukin-6 in Plaque Psoriasis and Its Possible Role in Disease Severity
The update reports on a completed study investigating interleukin-6 in plaque psoriasis and its potential link to disease severity.
-
CLINICAL_TRIALS research · 2025-05-31Clinical Trial Update: A Real-world Study of Deucravacitinib in the Treatment of Moderate to Severe Plaque Psoriasis With Eczematous Features
This clinical trial update describes a real-world study of Deucravacitinib for moderate-to-severe plaque psoriasis with eczematous features.…
-
CLINICAL_TRIALS research · 2025-05-30Clinical Trial Update: ROLL'YN-UST: an Observational Study in Patients Treated by Steqeyma®, an Ustekinumab Biosimilar
An observational study evaluating Steqeyma, a biosimilar of ustekinumab, in patients with Crohn's disease and plaque psoriasis; recruitment …
-
CLINICAL_TRIALS trial_result · 2025-05-25Clinical Trial Update: A Study of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis [Phase 2]
This document reports the completion of a Phase 2 trial evaluating JNJ-77242113 for moderate-to-severe plaque psoriasis. The snippet does no…
-
CLINICAL_TRIALS trial_result · 2025-05-25Clinical Trial Update: A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to Stelara® in Subject With Moderate to Severe Plaque Psoriasis [Phase 3]
Phase 3 study comparing SB17, a proposed ustekinumab biosimilar, to Stelara in adults with moderate-to-severe plaque psoriasis; results have…
-
FDA approval · 2025-05-22FDA Approved: STARJEMZA — Original Application (Hikma Pharmaceuticals USA Inc.)
FDA approved STARJEMZA (ustekinumab-hmny) from Hikma Pharmaceuticals USA Inc. as a biosimilar to ustekinumab, enabling marketing for the sam…
-
FDA label_change · 2025-05-22FDA Approved: ZORYVE — Supplemental Application (Arcutis Biotherapeutics, Inc.)
FDA notes a supplemental application for ZORYVE (roflumilast) by Arcutis Biotherapeutics to update the product label, likely to add or modif…
-
CLINICAL_TRIALS trial_result · 2025-05-22Clinical Trial Update: A Phase II Clinical Study of AC-201 Tablets in Subjects With Plaque Psoriasis [Phase 2]
This update covers a Phase II study of AC-201 tablets in subjects with plaque psoriasis, which has completed. The document notes the trial s…
-
CLINICAL_TRIALS trial_result · 2025-05-20Clinical Trial Update: A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms [Phase 3]
This clinical trial update reports the completion of a Phase 3 study of subcutaneous risankizumab in pediatric participants with moderate-to…
-
CLINICAL_TRIALS research · 2025-05-16Clinical Trial Update: Efficacy and Safety of Roflumilast Cream 0.3% in Subjects With Plaque Psoriasis: a Phase 3 Study [Phase 3]
Phase 3 clinical trial evaluating the efficacy and safety of roflumilast cream 0.3% for plaque psoriasis; currently recruiting.
-
CLINICAL_TRIALS trial_result · 2025-05-14Clinical Trial Update: Phase IV Study: Vunakizumab Efficacy and Safety in Moderate-to-severe Plaque Psoriasis
A Phase IV clinical trial is evaluating the efficacy and safety of vunakizumab for adults with moderate-to-severe plaque psoriasis and is cu…
-
CLINICAL_TRIALS trial_result · 2025-05-11Clinical Trial Update: Observational Real-world Evidence (RWE) Study to Assess Patient-reported Wellbeing Using Tildrakizumab in Live Setting - POSITIVE Study
This completed observational real-world evidence study assesses patient-reported wellbeing with tildrakizumab in plaque psoriasis. The POSIT…
-
FDA approval · 2025-04-30FDA Approved: USTEKINUMAB-TTWE — Original Application (Quallent Pharmaceuticals Health LLC)
FDA approves an original biologics license application for USTEKINUMAB-TTWE from Quallent Pharmaceuticals Health LLC.
-
FDA approval · 2025-04-30FDA Approved: SELARSDI — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for SELARSDI (ustekinumab-aekn) from Teva Pharmaceuticals USA, Inc., representing an approval of a b…
-
FDA approval · 2025-04-30FDA Approved: OTULFI — Supplemental Application (Fresenius Kabi USA, LLC)
FDA approved a supplemental application for OTULFI (ustekinumab-aauz) from Fresenius Kabi USA, LLC.